Manijeh Goldberg, PH.D., M.B.A., M.S.Peter Goldberg
CHAIRMAN OF THE BOARD
Manijeh is the Founder and CEO of Privo. She has over 20 years of experience in the biomedical industry, in large companies and five startups (one was acquired for $475M). She has developed US Key Opinion Leader (KOL) relationships, successfully lobbied to get PRV111 into a large, NIH-funded clinical study, planned and executed training, and helped drive on-time trial enrollment. Additionally, Manijeh is driving the execution of a second-generation Privo’s products. Her current focus is to conduct clinical trials, get PRV111’s second-generation products through the FDA, and explore initiating a second US clinical trial. Additional responsibilities include business development, general management, and driving the overall success of Privo’s research and products. Manijeh holds a Ph.D. in Biomedical Engineering, an MS in Health Sciences and Technology from Harvard Medical School, an MBA from MIT Sloan School of Management, and an MS in Computer Science and Mathematics.